SCHEMBL1772437

SCHEMBL1772437

CC1(C)NC(=O)N(c2ccc(S(N)(=O)=O)cc2)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 8/20 0.57
CA12 O43570 9/20 0.51
CA1 P00915 9/20 0.51
CA2 P00918 9/20 0.51
CA9 Q16790 9/20 0.51
SCN2A Q99250 1/20 0.49
CA7 P43166 2/20 0.47
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
TP53 P04637 1/20 0.45
CYP1A2 P05177 1/20 0.45
PGR P06401 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 1/20 0.45
ALOX12 P18054 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1772252 0.82 AR (0.57) ARCA12CA1CA2CA9
SCHEMBL1773397 0.81 AR (0.54) ARALDH1A1POLBMEN1LMNA
SCHEMBL4028165 0.80 AR (0.53) ARPOLBMEN1LMNATP53
SCHEMBL13039115 0.78 POLB (0.67) ARPOLBRAB9A
SCHEMBL1772860 0.77 LMNA (0.57) ARPOLBTDP1MEN1LMNA
SCHEMBL11470944 0.76 AR (0.64) ARALDH1A1POLBMEN1LMNA
SCHEMBL31330678 0.76 AR (0.64) ARPOLBMEN1LMNATP53
SCHEMBL13913495 0.76 AR (0.64) ARALDH1A1POLBMEN1LMNA
SCHEMBL11469297 0.76 AR (0.64) ARPOLBMEN1LMNATP53
SCHEMBL11461814 0.76 AR (0.64) ARALDH1A1POLBMEN1PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 US disclosed
EP-2242747-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 EP disclosed
WO-2009097997-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC AR 2449/4885CA12 4453/4885CA1 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.